Last reviewed · How we verify
Trikafta
At a glance
| Generic name | Trikafta |
|---|---|
| Also known as | Elexacaftor/Tezacaftor/Ivacaftor, elexacaftor, tezacaftor, ivacaftor |
| Sponsor | University of British Columbia |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Trikafta (PHASE2)
- Population Pharmacokinetics of Elexacaftor-tezacaftor-ivacaftor in a Paediatric Population
- Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis (PHASE4)
- Impact of Elexacaftor-Tezacaftor-Ivacaftor Treatment on Metabolic, Epigenetic and Fecal Microbiota Profiles in People With Cystic Fibrosis.
- Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers
- The PROMISE Pediatric Study 6 to 11 Years Old
- Sinus Disease in Young Children With Cystic Fibrosis
- Trikafta in Cystic Fibrosis Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Trikafta CI brief — competitive landscape report
- Trikafta updates RSS · CI watch RSS
- University of British Columbia portfolio CI